Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Food Recall Warning (Allergen) - Lebby brand Dark Chocolate Chickpea Snacks recalled due to undeclared milk


OTTAWA, ON , Nov. 25, 2022 Product photos are available: https://recalls-rappels.canada.ca/en/alert-recall/lebby-brand-dark-chocolate-chickpea-snacks-recalled-due-undeclared-milk

/CNW/ - 

Summary

Affected products

Brand

Product

Size

UPC

Codes

Lebby

Dark Chocolate Chickpea Snacks

99 g

8 55684 00623 3

BEST BY: 20 JAN 2023

LOT NO: 817080

 

BEST BY: 12 DEC 2023

LOT NO: 826972

 

Issue

The affected product is being recalled from the marketplace because it contains milk which is not declared on the label.

The recalled product has been sold nationally.

What you should do

Learn more:

Background

This recall was triggered by Canadian Food Inspection Agency test results.

There have been no reported reactions associated with the consumption of this product.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products.

The CFIA is verifying that industry is removing recalled products from the marketplace.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 07:30
The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its VISIONS 2024 conference at the Chicago Marriott Downtown Magnificent Mile on June 21?22, 2024. This biennial...

at 07:30
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new groundbreaking algorithm, SignalHF1, used...

at 07:30
The American Trucking Associations is calling attention to the negative consequences for highway safety and safety-sensitive industries that could result from the U.S. Drug Enforcement Administration's proposal to reschedule marijuana from a Schedule...

at 07:30
-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)-    Data to be presented from...

at 07:28
We are advised by OsteoStrong that journalists and other readers should disregard the news release, OsteoStrong Celebrates Success and Innovation at 11th Annual Global Franchise Owner Convention, issued May 9, 2024 over PR Newswire. SOURCE...

at 07:05
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...



News published on and distributed by: